| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| BioXcel Therapeutics Inc. | Dexmedetomidine (BXCL501) - (TRANQUILITY III) | Agitation associated with Alzheimer’s Disease | Phase 3 | Ongoing | Sublingual | Psychiatric |
| BioXcel Therapeutics Inc. | Dexmedetomidine (BXCL501) - (TRANQUILITY III) | Agitation associated with Alzheimer’s Disease | Phase 3 | Ongoing | Sublingual | Psychiatric |
| BioXcel Therapeutics Inc. | Dexmedetomidine (BXCL501) - (TRANQUILITY II) | Agitation associated with Alzheimer’s Disease | Phase 3 | Ongoing | Sublingual | Psychiatric |
| BioXcel Therapeutics Inc. | Dexmedetomidine (BXCL501) - (TRANQUILITY II) | Agitation associated with Alzheimer’s Disease | Phase 3 | Ongoing | Sublingual | Psychiatric |
| BioXcel Therapeutics Inc. | BXCL701 plus KEYTRUDA | Metastatic castration-resistant prostate cancer (mCRPC) | Phase 2 | Trial Planned | oral and intravenous | Oncology |
| BioXcel Therapeutics Inc. | Dexmedetomidine (BXCL501) - (PLACIDITY) | Agitation associated with delirium | Phase 2 | Ongoing | Sublingual | Psychiatric |
| BioXcel Therapeutics Inc. | Dexmedetomidine (BXCL501) - (TRANQUILITY III) | Agitation associated with Alzheimer’s Disease | Phase 3 | Ongoing | Sublingual | Psychiatric |
| BioXcel Therapeutics Inc. | Dexmedetomidine (BXCL501) - (TRANQUILITY II) | Agitation associated with Alzheimer’s Disease | Phase 3 | Ongoing | Sublingual | Psychiatric |